Abstract:Abstract Background and Aims In patients with severely decreased eGFR (stage 4-5 CKD), efficacy of treating patients to a lower blood pressure (BP) target is uncertain. The Systolic blood PRessure INtervention Trial (SPRINT) demonstrated lower rates of a composite cardiovascular (CVD) endpoint and death in the intensive treatment group with a target systolic blood pressure (SBP) of <120 mmHg. This study has influenced guidelines; the updated 2021 Kidney Disease Improving Global Outcomes (KDIGO) now suggest lowering the SBP to < 120 mmHg, if tolerated. In this study we set out to investigate the association between SBP and CVD in a large cohort of nephrology-referred patients with CKD stage 3-5. Method We included patients ≥18 years participating in the Swedish Renal Registry (SRR-CKD) who had a first registered eGFR <60 ml/min/1.73 m2 2006-2017 with at least one recorded BP measurement and two out-patient visits within one year. We excluded individuals with a recorded SBP <100 mmHg or prior kidney failure replacement treatment. After the initial one-year observation period, we followed patients until the primary or secondary outcome was attained, or until December 31, 2017. The achieved average systolic BP, measured during routine out-patient care using any standard electronic or manual blood pressure device, was categorized into a priori defined categories. To align with SPRINT, the primary endpoint was Major Cardiovascular Events (MACE) defined as the composite of first myocardial infarction (MI), non-MI acute coronary syndrome, stroke, heart failure, or death attributable to CVD. The secondary endpoints were the individual components of the primary composite endpoint, all-cause death, or a composite of the primary endpoint and death. Demographics, body mass index, underlying kidney disease, and laboratory values at the start of follow-up were obtained from the SRR-CKD. Information on comorbidity, including Charlson comorbidity index was gathered from a linkage with the National Patient Registry; medications were obtained from the National Prescribed drug register. The primary endpoint and secondary endpoints were assessed by cause-specific Cox proportional hazards regression, adjusting for age, sex, history of CVD, Charlson comorbidity, plasma albumin, phosphate, diuretics, RAASi, betablockers, eGFR, and diastolic blood pressure. Missing data were handled through multiple imputation. Results In total 15,668 patients with a median eGFR 23 ml/min/1.73 m2, mean age 71 years and 33% women were followed over a period of 2.8 years (IQR 1.4-5.0). There were 6359 patients (41%) experiencing the primary outcome; 2601 (17%) with a coronary artery event, 1427 (9%) MI, 1,345 (9%) cerebrovascular event, and 5,480 (35%) patients died. The unadjusted analysis showed a J-shaped relationship between SBP and the primary outcome, with the lowest risk of events in patients with SBP around 125 mmHg (Figure 1). In multivariable models, there was a higher risk of experiencing the primary outcome if the average SBP was >150 mmHg (HR 1.09;95%CI 1.0-1.19), the highest risk being in those with SBP above 160 mmHg (HR 1.40 with 95% CI 1.28-1.53) as compared to those with SBP 130-140 mmHg (Figure 2). We observed 30% lower risk of MI when the SBP was 100–120 mmHg after adjustments (HR 0.70 (95% CI 0.56–0.88) as compared to 130–140, and higher risk of MI at SBP >160 mmHg (1.78; 1.49–2.12) with 11% higher risk of MI with every 10 mmHg increase in SBP (HR 1.11; 1.07–1.14). The other cardiovascular endpoints, including all-cause mortality showed a similar pattern as the primary composite endpoint. Conclusion In patients with advanced stage CKD, SBP <120 mmHg is associated with lower risk of MI, but not with lower risk of other cardiovascular outcomes or all-cause mortality. A SBP >140 mmHg was associated with higher risk of most cardiovascular events including cardiovascular mortality and all-cause mortality.

Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study

Effect of Intensive Blood Pressure Control on Kidney Outcomes: Long-Term Electronic Health Record-Based Post-Trial Follow-Up of SPRINT

Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events

Kidney tubule health, mineral metabolism and adverse events in persons with CKD in SPRINT

Final Report of a Trial of Intensive versus Standard Blood-Pressure Control

Concordance between clinical outcomes in the Systolic Blood Pressure Intervention Trial and in the electronic health record

#2984 ACHIEVED BLOOD PRESSURE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ADVANCED STAGE CHRONIC KIDNEY DISEASE

Markers of Kidney Tubular Secretion and Risk of Adverse Events in SPRINT Participants with CKD

Effects of intensive blood pressure control on mortality and cardiorenal function in chronic kidney disease patients

The effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in critically ill patients with acute kidney injury: An observational study using the MIMIC database

Effect of Intensive Blood Pressure Lowering on the Risk of Incident Silent Myocardial Infarction: A Post Hoc Analysis of a Randomized Controlled Trial

Role of Diuretics in Cardiovascular Events and Mortality in Systolic Blood Pressure Intervention Trial

Systolic Blood Pressure Reduction and Acute Kidney Injury in Intracerebral Hemorrhage.

Early, Individualized Recommendations for Hospitalized Patients With Acute Kidney Injury: A Randomized Clinical Trial

Effect of Intensive Blood Pressure Control on Troponin and Natriuretic Peptide Levels: Findings From SPRINT

The Impact of Admission Serum Creatinine on Major Adverse Clinical Events in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention

The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)

Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy

Cause-Specific Mortality in Patients With Advanced Chronic Kidney Disease in the ISCHEMIA-CKD Trial

Systolic Blood Pressure and the Risk of Kidney Replacement Therapy and Mortality in Patients with Chronic Kidney Disease Stages 4-5

Urine Ammonium Concentrations and Cardiovascular and Kidney Outcomes in Systolic Blood Pressure Intervention Trial Participants with CKD